Fundraising Fox

Adam Goulburn

Investor

Managing Partner at Dimension Capital

New York, New York

Writes $1M – $10M checks · typically $2M

Founded3ScanAuthoreaCareGuardianEikon TherapeuticsPager

About

Adam Goulburn, a PhD neuroscientist-turned-investor who founded or incubated Cajal Neuroscience and Kallyope, takes operational roles to build technically ambitious, biology-digitization ventures (microbiome, brain-computer interfaces, patient-accelerated drug development).

Invests in

AI & Machine LearningBiotechData & InfrastructureRoboticsSaaS

Experience

  1. DimensionCo-Foundercurrent2022 — presentNew York
  2. Lux CapitalVenture Partner2022
  3. Lux CapitalPartner2015 — 2022
  4. Lux CapitalPrincipal2014 — 2015New York City Metropolitan Area
  5. Lux CapitalSenior Associate2012 — 2014New York City Metropolitan Area
  6. Lux CapitalAssociate2011 — 2012New York
  7. VNV Bio (now Aera Therapeutics)Founding CEO2018 — 2021New York, United States
  8. KallyopeFounding CEO2014 — 2015New York
  9. Weill Cornell Medical CollegePost-Doctoral Associate2010 — 2011New York

Education

  1. Monash UniversityPhD, Stem Cell Research2006 — 2010
  2. UNSWBachelor of Commerce / Bachelor of Science, International Business2001 — 2005

Skills & more

Venture Capital35Lifesciences8Entrepreneurship25Regenerative Medicine4Biotechnology28Commercialization15Start-ups40Digital Health7

From Adam's professional profile.

Same school

Shared employers

Deals · 5

Variant BioBoard seat

via Dimension Capital · filed Oct 2019 · $31.5M raise

Drone Racing LeagueBoard seat

via Dimension Capital · filed Jun 2019 · $50M raise

3ScanBoard seat

via Dimension Capital · filed Jul 2016 · $14M raise

AuthoreaBoard seat

via Dimension Capital · filed Jan 2016 · $1.5M raise

press ↗

CareGuardianBoard seat

via Dimension Capital · filed Jan 2016 · $30.3M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Dimension Capital

Network10

Investors connected to Adam in public investor directories — a warm-intro map.